Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immune Checkpoints and Ncrnas: Pioneering Immunotherapy Approaches for Hematological Malignancies Publisher



Anvari S1 ; Nikbakht M2 ; Vaezi M3 ; Aminikafiabad S1 ; Ahmadvand M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
  2. 2. Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Hematology, Oncology, and Stem Cell Transplantation Research Center Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Cancer Cell International Published:2024


Abstract

Hematological malignancies are typically treated with chemotherapy and radiotherapy as the first-line conventional therapies. However, non-coding RNAs (ncRNAs) are a rapidly expanding field of study in cancer biology that influences the growth, differentiation, and proliferation of tumors by targeting immunological checkpoints. This study reviews the results of studies (from 2012 to 2024) that consider the immune checkpoints and ncRNAs in relation to hematological malignancies receiving immunotherapy. This article provides a summary of the latest advancements in immunotherapy for treating hematological malignancies, focusing on the role of immune checkpoints and ncRNAs in the immune response and their capacity for innovative strategies. The paper also discusses the function of immune checkpoints in maintaining immune homeostasis and how their dysregulation can contribute to developing leukemia and lymphoma. Finally, this research concludes with a discussion on the obstacles and future directions in this rapidly evolving field, emphasizing the need for continued research to fully harness the capacity of immune checkpoints and ncRNAs in immunotherapy for hematological malignancies. © The Author(s) 2024.
Related Docs
View other Related Docs
1. The Promising Role of Non-Coding Rnas As Biomarkers and Therapeutic Targets for Leukemia, Genes (2023)
2. Non-Coding Rnas in Leukemia Drug Resistance: New Perspectives on Molecular Mechanisms and Signaling Pathways, Annals of Hematology (2024)
3. Microrna in Leukemia: Tumor Suppressors and Oncogenes With Prognostic Potential, Journal of Cellular Physiology (2019)
4. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
5. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
6. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
7. Long Non-Coding Rna Signatures in Lymphopoiesis and Lymphoid Malignancies, Non-coding RNA (2023)
8. Immune Checkpoint Inhibitors Therapy As the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape, Critical Reviews in Oncology/Hematology (2024)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (21)
Hamid Reza Mirzaei (11)
Other Related Docs
9. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer, International Immunopharmacology (2020)
10. Non-Coding Rnas: Emerging Contributors to Chemoresistance in Chronic Myeloid Leukemia, Leukemia Research Reports (2025)
11. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)
12. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
13. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
14. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
15. Immune Checkpoints and Graves’ Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review, Journal of Ophthalmic and Vision Research (2024)
16. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
17. Tumor Immunology, Clinical Immunology (2022)
18. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
19. Circular Rnas in Alzheimer’S Disease: A New Perspective of Diagnostic and Therapeutic Targets, CNS and Neurological Disorders - Drug Targets (2023)
20. The Prospect of Targeting T Cell Immunoglobulin and Mucin-Domain Containing-3 in Renal Cell Carcinoma Immunotherapy, Scandinavian Journal of Immunology (2022)
21. Immune Checkpoints and Reproductive Immunology: Pioneers in the Future Therapy of Infertility Related Disorders?, International Immunopharmacology (2021)
22. A Systematic Review and Meta-Analysis of Immune Checkpoint Therapy in Relapsed or Refractory Non-Hodgkin Lymphoma; a Friend or Foe?, Translational Oncology (2023)
23. Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma, Expert Review of Anticancer Therapy (2021)
24. Gene-Knocked Out Chimeric Antigen Receptor (Car) T Cells: Tuning up for the Next Generation Cancer Immunotherapy, Cancer Letters (2018)
25. Efficacy of Nivolumab As Checkpoint Inhibitor Drug on Survival Rate of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: A Meta-Analysis of Prospective Clinical Study, Clinical and Translational Oncology (2019)
26. New Insights Into the Long Non-Coding Rnas Dependent Modulation of Heart Failure and Cardiac Hypertrophy: From Molecular Function to Diagnosis and Treatment, Current Medicinal Chemistry (2024)
27. Microrna and Gynecological Cancers: Focus on Mir-195, Pathology Research and Practice (2023)
28. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
29. An Overview of Long Noncoding Rnas: Biology, Functions, Therapeutics, Analysis Methods, and Bioinformatics Tools, Cell Biochemistry and Function (2022)
30. Exosomes and Non-Coding Rnas: Exploring Their Roles in Human Myocardial Dysfunction, Biomedicine and Pharmacotherapy (2025)
31. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
32. Recent Progress in the Immunotherapy of Hepatocellular Carcinoma: Non-Coding Rna-Based Immunotherapy May Improve the Outcome, Biomedicine and Pharmacotherapy (2023)
33. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
34. Enhancing Sirna Cancer Therapy: Multifaceted Strategies With Lipid and Polymer-Based Carrier Systems, International Journal of Pharmaceutics (2024)
35. Immune Checkpoint Inhibitors and Cardiotoxicity: Possible Mechanisms, Manifestations, Diagnosis and Management, Expert Review of Anticancer Therapy (2021)
36. Non-Coding Rnas and Aquaporin 4: Their Role in the Pathogenesis of Neurological Disorders, Neurochemical Research (2024)
37. Therapeutic and Diagnostic Applications of Exosomes in Colorectal Cancer, Medical Oncology (2024)
38. Targeted Knockdown of Tim3 by Short Hairpin Rnas Improves the Function of Anti-Mesothelin Car T Cells, Molecular Immunology (2021)
39. Melatonin Affects the Expression of Microrna-21: A Mini-Review of Current Evidence, Pathology Research and Practice (2024)
40. Impact of Helicobacter Pylori Infection on the Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis, Immunotherapy (2023)
41. Crosstalk Between Lncrnas in the Apoptotic Pathway and Therapeutic Targets in Cancer, Cytokine and Growth Factor Reviews (2022)
42. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
43. Gene Therapy in Glioblastoma Multiforme: Can It Be a Role Changer?, Heliyon (2024)
44. Blockage of Immune Checkpoint Molecules Increases T-Cell Priming Potential of Dendritic Cell Vaccine, Immunology (2020)
45. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
46. Long Non-Coding Rnas As Epigenetic Regulators in Cancer, Current Pharmaceutical Design (2019)
47. Melatonin Targeting Non-Coding Rnas in Cancer: Focus on Mechanisms and Potential Therapeutic Targets, European Journal of Pharmacology (2023)
48. State of the Art in Microrna As Diagnostic and Therapeutic Biomarkers in Chronic Lymphocytic Leukemia, Journal of Cellular Physiology (2018)
49. The Potential Role of Circular Rnas in Regulating P53 in Different Types of Cancers, Pathology Research and Practice (2024)
50. Recent Advances in Non-Small Cell Lung Cancer Targeted Therapy; an Update Review, Cancer Cell International (2023)